UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Ubiquitination is widely involved in the progression of hepatocellular carcinoma (HCC) by regulating various cellular processes. However, systematic strategies for screening core ubiquitin-related genes, clarifying their functions and mechanisms, and ultimately developing potential therapeutics for patients with HCC are still lacking. Methods: Cox and LASSO regression analyses were performed to construct a ubiquitin-related gene prediction model for HCC. Loss- and gain-of-function studies, transcriptomic and metabolomics analysis were used to explore the function and mechanism of UBE2S on HCC cell glycolysis and growth. Results: Based on 1,423 ubiquitin-related genes, a four-gene signature was successfully constructed to evaluate the prognosis of patients with HCC. UBE2S was identified in this signature with the potential to predict the survival of patients with HCC. E2F2 transcriptionally upregulated UBE2S expression by directly binding to its promoter. UBE2S positively regulated glycolysis in a HIF-1α-dependent manner, thus promoting the proliferation of HCC cells. Mechanistically, UBE2S enhanced K11-linkage polyubiquitination at lysine residues 171 and 196 of VHL independent of E3 ligase, thereby indirectly stabilizing HIF-1α protein levels by mediating the degradation of VHL by the proteasome. In particular, the combination of cephalomannine, a small molecule compound that inhibits the expression of UBE2S, and PX-478, an inhibitor of HIF-1α, significantly improved the anti-tumor efficacy. Conclusions: UBE2S is identified as a key biomarker in HCC among the thousands of ubiquitin-related genes and promotes glycolysis by E3 enzyme-independent ubiquitination, thus serving as a therapeutic target for the treatment of HCC.
Abstract
Background/Aims: Ubiquitination is widely involved in the progression of hepatocellular carcinoma (HCC) by regulating various cellular processes. However, systematic strategies for screening core ubiquitin-related genes, clarifying their functions and mechanisms, and ultimately developing potential therapeutics for patients with HCC are still lacking. Methods: Cox and LASSO regression analyses were performed to construct a ubiquitin-related gene prediction model for HCC. Loss- and gain-of-function studies, transcriptomic and metabolomics analysis were used to explore the function and mechanism of UBE2S on HCC cell glycolysis and growth. Results: Based on 1,423 ubiquitin-related genes, a four-gene signature was successfully constructed to evaluate the prognosis of patients with HCC. UBE2S was identified in this signature with the potential to predict the survival of patients with HCC. E2F2 transcriptionally upregulated UBE2S expression by directly binding to its promoter. UBE2S positively regulated glycolysis in a HIF-1α-dependent manner, thus promoting the proliferation of HCC cells. Mechanistically, UBE2S enhanced K11-linkage polyubiquitination at lysine residues 171 and 196 of VHL independent of E3 ligase, thereby indirectly stabilizing HIF-1α protein levels by mediating the degradation of VHL by the proteasome. In particular, the combination of cephalomannine, a small molecule compound that inhibits the expression of UBE2S, and PX-478, an inhibitor of HIF-1α, significantly improved the anti-tumor efficacy. Conclusions: UBE2S is identified as a key biomarker in HCC among the thousands of ubiquitin-related genes and promotes glycolysis by E3 enzyme-independent ubiquitination, thus serving as a therapeutic target for the treatment of HCC.
참고문헌 (43)
- Senft D, "Ubiquitin ligases in oncogenic transformation and cancer therapy", Nat Rev Cancer, 18, pp.69~88 (2018)
- Chen Q, "SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma", Cell Death Differ, 30, pp.137~151 (2023)
- Wu H, "Tumor necrosis factor receptor-associated factor 6 promotes hepatocarcinogenesis by interacting with histone deacetylase 3 to enhance c-Myc gene expression and protein stability", Hepatology, 71, pp.148~163 (2020)
- Liu Y, "TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway", Nat Commun, 11, pp.348~ (2020)
- Ge C, "The BRUCE-atr signaling axis is required for accurate DNA replication and suppression of liver cancer development", Hepatology, 69, pp.2608~2622 (2019)
- Chen YH, "VPS34 K29", K48 branched ubiquitination governed by UBE3C and TRABID regulates autophagy, proteostasis and liver metabolism, 2021, pp.12, 1322~
- Vogel A, "Hepatocellular carcinoma", Lancet, 400, pp.1345~1362 (2022)
- Piñero F, "Biomarkers in hepatocellular carcinoma : Diagnosis, prognosis and treatment response assessment", Cells, 9, pp.1370~ (2020)
- Komander D, "The ubiquitin code", Annu Rev Biochem, 81, pp.203~229 (2012)
- Komander D, "Breaking the chains : structure and function of the deubiquitinases", Nat Rev Mol Cell Biol, 10, pp.550~563 (2009)
- Popovic D, "Ubiquitination in disease pathogenesis and treatment", Nat Med, 20, pp.1242~1253 (2014)
- Clague MJ, "The demographics of the ubiquitin system", Trends Cell Biol, 25, pp.417~426 (2015)
- Ciechanover A, "The unravelling of the ubiquitin system", Nat Rev Mol Cell Biol, 16, pp.322~324 (2015)
- Dikic I, "An expanded lexicon for the ubiquitin code", Nat Rev Mol Cell Biol, 24, pp.273~287 (2023)
- Deng L, "The role of ubiquitination in tumorigenesis and targeted drug discovery", Signal Transduct Target Ther, 5, pp.11~ (2020)
- Medvar B, "Comprehensive database of human E3 ubiquitin ligases : application to aquaporin-2 regulation", Physiol Genomics, 48, pp.502~512 (2016)
- Vaupel P, "The Warburg effect : essential part of metabolic reprogramming and central contributor to cancer progression", Int J Radiat Biol, 95, pp.912~919 (2019)
- Denko NC, "Hypoxia, HIF1 and glucose metabolism in the solid tumour", Nat Rev Cancer, 8, pp.705~713 (2008)
- Maxwell PH, "The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis", Nature, 399, pp.271~275 (1999)
- Wickliffe KE, "The mechanism of linkage-specific ubiquitin chain elongation by a single-subunit E2", Cell, 144, pp.769~781 (2011)
- Brown NG, "Mechanism of polyubiquitination by human anaphase-promoting complex : RING repurposing for ubiquitin chain assembly", Mol Cell, 56, pp.246~260 (2014)
- Sheng Y, "A human ubiquitin conjugating enzyme(E2)-HECT E3 ligase structure-function screen", Mol Cell Proteomics, 11, pp.329~341 (2012)
- Yau R, "The increasing complexity of the ubiquitin code", Nat Cell Biol, 18, pp.579~586 (2016)
- Zhang RY, "UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development", Signal Transduct Target Ther, 6, pp.64~ (2021)
- Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.6~ (2021)
- Chen HZ, "The orphan nuclear receptor TR3", Nur77 regulates ER stress and induces apoptosis via interaction with TRAPγ, 2013, pp.45, 1600~1609
- Desaki R, "As a novel prognostic marker, cysteine", histidinerich 1(CYHR1)is a therapeutic target in patients with esophageal squamous cell carcinoma, 2017, pp.24, 586~593
- Pan YH, "UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma", Biochem Biophys Res Commun, 503, pp.895~902 (2018)
- Bochis OV, "The role of Skp2 and its substrate CDKN1B(p27)in colorectal cancer", J Gastrointestin Liver Dis, 24, pp.225~234 (2015)
- Li Y, "Effect of human papillomavirus seropositivity and E2F2 promoter variants on risk of squamous cell carcinomas of oropharynx and oral cavity", Carcinogenesis, 37, pp.1070~1078 (2016)
- Wang S, "CDCA2protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma", Oncogene, 40, pp.4368~4383 (2021)
- Dong Y, "MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma", Mol Med Rep, 12, pp.1016~1022 (2015)
- Fang ZQ, "MiR-490-5p inhibits the metastasis of hepatocellular carcinoma by down-regulating E2F2 and ECT2", J Cell Biochem, 119, pp.8317~8324 (2018)
- Shen S, "Expression and prognostic role of E2F2 in hepatocellular carcinoma", Int J Gen Med, 14, pp.8463~8472 (2021)
- Zeng Z, "Increased E2F2 predicts poor prognosis in patients with HCC based on TCGA data", BMC Cancer, 20, pp.1037~ (2020)
- Stewart MD, "E2 enzymes : more than just middle men", Cell Res, 26, pp.423~440 (2016)
- Sampson C, "The roles of E3 ubiquitin ligases in cancer progression and targeted therapy", Clin Transl Med, 13, pp.e1204~ (2023)
- Sun L, "E3-Independent constitutive monoubiquitination complements histone methyltransferase activity of SETDB1", Mol Cell, 62, pp.958~966 (2016)
- Cheng B, "Recent advances in small molecule based cancer immunotherapy", Eur J Med Chem, 157, pp.582~598 (2018)
- Welsh S, "Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha", Mol Cancer Ther, 3, pp.233~244 (2004)
- Lee K, "A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor", Arch Pharm Res, 34, pp.1583~1585 (2011)
- Ban HS, "Hypoxia-inducible factor inhibitors : a survey of recent patented compounds(2004-2010)", Expert Opin Ther Pat, 21, pp.131~146 (2011)
- Wu J, "UBE2S promotes malignant properties via VHL", HIF-1α and VHL, STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma, pp.Cancer Med, 2023[DOI]